CAS: 770-30-9; 4-Amino-2-(Methylthio)Pyrimidine-5-Carbonitrile

该化合物是一种有机化合物,具有以氨基氨基化合物,甲基硫磷组和西诺组替代的火利米丁环环状环状,其特征是,该化合物的七环结构包括环内氮原子,有助于其潜在的生物活动.氨基氨基生物组的存在表明,它可能参与氢联结,而西诺组则能够加强其极地溶剂的再活性和溶性.甲基硫基组引入了硫磺原子,可影响该化合物的电子特性和消毒效应.该物质对药用化学和农业应用具有兴趣,因为其衍生物的精密性能和再活性经常被探究其药用特性.其合成和活性可能受到现有功能组的影响,使其在各种化学反应中成为一种灵敏化合物.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

2-methylisothiourea sulphate Ethoxymethylenemalononitrile S-Methylisothiourea sulfate S-methylisothiourea hemisulphate 4-amino-2-methanesulfonyl-pyrimidine-5-carbonitrile 4-[(5-cyano-2-methylsulfanyl-pyrimidin-4-ylamino)-methyl]-benzoic acid methyl ester 4-amino-2-(methylthio)pyrimidine-5-carbothioamide 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde

合成工艺路线路线简述

    📜S-甲基异硫脲硫酸盐,乙氧基亚甲基丙二腈置于n,N-二异丙基乙胺体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应生成 4-氨基-2-(甲基硫代)嘧啶-5-腈
    参考文献:吡唑并[3,4-D]嘧啶和嘧啶并[4,5-D]嘧啶-4-酮衍生物的简便合成
    标题:吡唑并[3,4-D]嘧啶和嘧啶并[4,5-D]嘧啶-4-酮衍生物的简便合成
    摘要:摘要 吡唑并嘧啶和嘧啶并嘧啶衍生物已显示出广泛的生物活性,例如作为 A1 腺苷受体,激酶插入域受体 (Kdr),劳斯肉瘤癌基因 (Src),表皮生长因子受体 (Egfr),抗增殖剂,二氢叶酸还原酶 (Dhfr).),抗微生物,抗真菌和脂质过氧化.由于这种广泛的活性,我们合成了吡唑并[3,4-D]嘧啶和嘧啶并[4,5-D]嘧啶-4-One衍生物.
    DOI:10.1080/00397910600773726

    海关参考信息

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1126/science.abo7201
    摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知